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Introduction
In the pediatric clinical setting, the parent/guard-
ian will almost always be the authorized representa-
tive and designated recipient of clinical and research 
results, making the issue of to whom results should 
be returned in the pediatric setting less complex 
than in adult settings. It is also clear that, in genomic 
research related to pediatric diseases such as can-
cer, results may be of considerable clinical, ethical, 
and personal significance for parents in a number of 
ways, including a genomic explanation of the origin 
of their child’s cancer, implications for the genetic 
testing and medical care of other siblings and of 
the parents themselves, and reproductive planning 
with regard to the recurrence risk for future chil-
dren to have an increased risk of cancer. However, 
what remains unclear is which results should be dis-
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closed, and under what circumstances, to parents of 
deceased children.
Generally, whether and to whom results of genomic 
analysis should be returned after a research subject 
has died is problematic. According to current federal 
regulation of human subjects of research, when a 
research subject dies, he or she is no longer a human 
research subject. Institutional review 
boards (IRBs) therefore do not provide 
guidance regarding return of genomic 
results in this scenario because doing so 
is not under their purview. There are no 
clear guidelines for how to responsibly 
manage this problem. 
The improvement of quality in the 
processes of patient care emphasizes the 
professionally responsible minimiza-
tion of variation in the patient care pro-
cesses.1 In the absence of guidance for 
investigators and IRBs that oversee research in pedi-
atric genomics, there is potential for great variation in 
approaches from institution to institution and even 
among investigators within a single institution. Such 
uncontrolled variation can create ethical conflicts, but 
is preventable. The purpose of this paper is to provide 
a preventive ethics approach in the return of genomic 
results to parents in the research setting.2 It is based 
on our long-term experience with research protocols 
focused on genetic susceptibility to childhood cancer. 
Selective Literature Review
To set the stage for the proposed preventive ethics 
approach, we selectively review the current literature. 
Our goal in doing so is not to undertake a systematic 
review of the literature but to place the preventive 
ethics approach in the context of proposals to manage 
return of results in the clinical and research setting, 
and the preferences of research subjects and their par-
ents and family members.
A. Return of Results in the Clinical Setting
In the clinical healthcare setting, it has been sug-
gested that a plan for the return of results, including 
genetic test results, in the event of the patient’s death 
be agreed upon during pre-test counseling, either 
by a genetic counselor or a physician.3 In the United 
States, under the Health Insurance Portability and 
Accountability Act (HIPAA) Privacy Rule, protected 
health information (PHI) can legally be shared with 
family members post-mortem, unless doing so is 
inconsistent with the prior expressed preferences of 
the deceased.4 The American Medical Association also 
advocates for maintaining confidentiality of medical 
information post-mortem, and suggests that decisions 
about disclosure should balance the potential harm to 
individuals who may be identified by the information, 
potential benefit to at-risk individuals, the patient’s 
previously stated wishes, and the impact of disclo-
sure on the deceased’s reputation.5 Regarding genetic 
information, two United States state court cases have 
addressed the obligation of physicians to warn fam-
ily members of a genetic risk of disease, with differ-
ent outcomes. In New Jersey, it was decided that there 
is a duty to warn immediate family members of the 
risk of inheriting a genetic condition. However, the 
Florida Supreme Court determined that this duty was 
satisfied by warning the patient of the potential risk 
to family members.6 There may also be state specific 
statutes that address disclosure of genetic informa-
tion after death. For example, Texas state law speci-
fies, “genetic information may be disclosed without an 
authorization…if the disclosure is: made to provide 
genetic information relating to a decedent and the dis-
closure is made to the blood relatives of the decedent 
for medical diagnosis.”7 
B. Return of Results in the Research Setting 
The considerations regarding return of results fol-
lowing a patient’s death become more complex in 
the research setting. In the United States, the regula-
tions for the protection of human research subjects do 
not address disclosure of research results after death 
because once an individual is deceased, he or she is 
no longer considered a human subject.8 The HIPAA 
Privacy Rule allows for the disclosure of PHI, includ-
ing research results, to family members and to the 
authorized representative of the deceased, who then 
may grant permission to release such information to 
other individuals.
Studies have shown that in most cases research par-
ticipants and family members feel that research results 
should be shared with family members after death. In 
an assessment of adult biobank participants’ prefer-
ences, most individuals expressed a desire for their 
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genetic research results to be returned to their next of 
kin or a specified representative after their death, and 
expressed a desire to share the results with their pri-
mary care physician.9 A survey of the family members 
of deceased adult men previously enrolled in BRCA2 
studies felt they had a right to know results that may 
have an impact upon their personal risk management 
decisions.10 Parents of children with cancer and inher-
ited diseases expressed a strong right to receive results 
of genomic research directly related to their child’s 
condition, including the situation in which a child has 
died.11 
Given the lack of clear guidelines in this area, we 
describe our experience over 15 years of human sub-
jects research related to childhood cancer genetics 
and then provide recommendations for a preventive 
ethics approach for researchers planning genomic 
research where return of results after the death of a 
child should be considered.
Illustrative Case Studies of the Challenges 
of Return of Results in Pediatric Genomic 
Research
A. Two Cases of Rare Disorders Studies 
Rothmund-Thomson Syndrome (RTS) is a rare auto-
somal recessive condition characterized by a dis-
tinctive rash (poikiloderma) which first appears in 
infancy. Other associated features include short stat-
ure, abnormalities of the hair and nails, juvenile cata-
racts, and skeletal abnormalities.12 In the late 1990s, 
case studies began to accumulate demonstrating the 
connection between RTS and osteosarcoma.13 In 1998, 
investigators at Baylor College of Medicine (BCM) ini-
tiated a human subjects protocol to study the molec-
ular basis of familial cancer susceptibility (H7207), 
with an initial focus on identifying the cancer risk in 
RTS and identifying the causative gene. Given that 
all research procedures were being performed in a 
laboratory not regulated by the Clinical Laboratory 
and Improvement Amendments (CLIA) law, and the 
goal of the project was gene discovery, the protocol, 
consent forms and the consent process clearly stated 
that there were no plans to provide results to subjects 
or their physicians. The protocol was not specific to 
RTS; investigators also included families with other 
unusual patterns of childhood cancer suggestive of an 
underlying cancer susceptibility gene as described in 
Case 2.
In 1999, the first report in Nature Genetics iden-
tified RECQL4 mutations in 4 of 6 of RTS families 
analyzed.14 At that time, BCM investigators began to 
perform research sequencing of the RECQL4 gene 
of all RTS families enrolled in H7207, resulting in 
the identification of pathogenic mutations in about 
65% of the patients with RTS and including almost 
all patients with RTS and osteosarcoma.15 During this 
same time period, study families and their physicians 
who had learned of the discoveries routinely requested 
RECQL4 test results from study investigators. Despite 
extensive efforts to make clear at the time of study 
entry that research results would not be provided, 
many families and their physicians were disheartened 
when their requests were denied. 
Case 1: In 1999, the physician for an RTS patient 
contacted the BCM investigators about joining the 
H7207 study. The samples from the child and parents 
were included in the molecular analysis of the RECLQ4 
gene and pathogenic mutations were identified in 
the child’s sample as part of that study. In 2003, the 
child died from osteosarcoma, the malignancy most 
frequently seen in RTS patients. Several months later, 
the parents and their physicians contacted the BCM 
investigators, as the parents were currently expecting 
a second child and requested the RECQL4 research 
information. The requested information was specifi-
cally for prenatal counseling and testing purposes as 
the pregnancy was at 25% risk of being affected by 
RTS (given the autosomal recessive nature of the dis-
ease). The family had identified a clinical laboratory 
in their home country that was willing to confirm 
research findings provided by the investigators. The 
H7207 study investigators retained the only biologi-
cal sample that existed from the affected child (now 
deceased) and, at the time, no lab was offering paren-
tal RECQL4 testing outside of confirming research 
results. Given these circumstances, BCM study staff 
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rapidly requested and obtained permission from the 
BCM IRB to provide these RECQL4 research results 
to the physicians and laboratory willing to conduct 
confirmatory clinical testing. Parental carrier status 
was confirmed and the parents were informed that the 
fetus was found to carry both pathogenic mutations as 
had their child with RTS. 
Change in protocol: After this experience, the 
H7207 protocol and consent was modified to ask each 
subject (or parent) whether they wanted to be pro-
vided return of results and to whom the results should 
be returned to (the family or to a health care provider). 
Research results would be returned to families only if 
the research findings had undergone peer review for 
publication in a scientific journal and were found to be 
“clinically important.” This differs from the approach 
used by some institutions where results must be 
returned to families in order to be included in a publi-
cation. Upon return, it is recommended to the parents 
that the research results be confirmed in a laboratory 
subject to CLIA prior to clinical usage. 
Case 2: Over a period of several years, two siblings 
in early childhood were diagnosed with advanced 
tumors of the same organ, which is an extremely rare 
finding and highly suggestive of a genetic predisposi-
tion to cancer. As a part of the clinical work-up after 
the second sibling was diagnosed, genetic testing for 
all syndromes currently known to be associated with 
this pediatric tumor type revealed no significant find-
ings. On the advent of whole exome/genome sequenc-
ing research initiatives, family members were entered 
into research studies at BCM (parents entered a BCM 
genome sequencing study for Mendelian disorders) 
and another institution caring for the child. Investiga-
tors from both institutions collaborated on a research 
study to try to identify the underlying cause of cancer 
in the family. Extensive use of genomic technologies 
(whole exome and genome sequencing of blood and 
tumor samples) was performed. Despite this effort, 
the etiology of the pediatric cancers in this family 
remains unclear. The absence of answers to the ques-
tion, “why?” has been difficult for the family. They are 
left with concerns for risks to their remaining children 
and concerns of having additional affected children 
without a known genetic diagnosis. Over many years, 
the parents of these children have contacted BCM 
researchers at least yearly requesting updated infor-
mation including information that might be relevant 
to other medical problems within the family, or ques-
tions about reports in the lay press about new genetic 
findings (both common and rare genetic changes) and 
their relevance to the cancer risk within the family.
Summary of experience from rare disorder research: 
These cases illustrate the additional complexity of 
research studies for rare diseases where there is fre-
quent interaction between patients, caretakers and 
a small number of researchers. Unlike biobanks or 
genome-wide association (GWAS) studies, the infor-
mation that can potentially be elicited has a higher 
likelihood to directly have an impact upon families. 
Furthermore, the principal investigators may have 
direct and long-term relationships with families, 
furthering the likelihood of opportunities to disclose 
results. Case 1 shows that participating subjects and 
their physicians may have expectations to receive 
results, even when agreeing to enroll in a study that 
explicitly states that results will not be returned. This 
is consistent with studies that have shown that partici-
pants have difficulties in comprehension when giving 
informed consent in the setting of clinical trials. This 
includes confusion regarding the purpose and nature 
of trials, study procedures, and confusion between 
clinical trial steps and clinical care.16 Both cases illus-
trate that over time families may be faced with uncer-
tainties, such as with family planning, and may turn to 
study investigators in the hope of obtaining relevant 
information. Moreover, if a protocol excludes return of 
results, then there may be scenarios in which clinically 
relevant information would be withheld from partici-
pants who may not have other means of obtaining that 
information. This was illustrated in Case 1 where the 
research results provided diagnostic information to 
the family in a successive pregnancy that would have 
otherwise been unavailable. 
Parental interest in return of results: Consistent 
with published reports, parents are very interested 
in the return of results. Since 2003, when return of 
results was introduced into H7207, an additional 352 
individuals (predominantly pediatric patients) have 
been enrolled and 345 (98%) of the adult subjects or 
the parents of the pediatric age subjects have requested 
that clinically significant results be returned. Of those 
who elected to receive results, 15% wanted the results 
returned to a health care provider of their choice, 6% 
asked that results be returned both to themselves 
and a health care provider, and 79% requested that 
results be returned to them directly. However, Case 2 
highlights the scenario, which is true in many fami-
lies, where despite the possibility of returning results, 
clinically relevant results may not become available. 
The definition of what is clinically relevant may also 
differ (or be unclear) between families, investigators, 
and institutions. 
The investigators in these cases may also be the clin-
ical providers for study patients and families. There-
fore, the fine line between research and clinical care 
may be more frequently blurred. As genomic research 
studies begin to utilize clinical testing in the context 
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of a research protocol, the lines between clinic and 
research become more difficult to distinguish. The 
next section will address three case examples of return 
of genomic results of a clinically available test in the 
setting of a research study. 
B. Baylor College of Medicine Advancing Sequencing 
in Childhood Cancer Care (BASIC3)
The National Human Genome Research Institute 
(NHGRI) and National Cancer Institute (NCI) funded 
Baylor College of Medicine Advancing Sequencing in 
Childhood Cancer Care (BASIC3) study, one of the 
NIH Clinical Sequencing Exploratory Research pro-
gram projects, examines the clinical utility of tumor 
and germline WES in the care of childhood cancer 
patients. The human subjects protocol (H30755) was 
initially approved in 2012 by the BCM IRB, which is 
also the IRB for Texas Children’s Hospital (TCH), the 
study clinical site. Study enrollment is offered to all 
patients with newly-diagnosed solid tumors (includ-
ing central nervous system [CNS] tumors) under the 
age of 18 years who undergo their initial tumor surgery 
and have ongoing oncologic treatment at TCH, and 
have at least one parent who speaks English or Span-
ish.17 As a part of the study, whole exome sequencing 
is performed on a sample of both blood and tumor tis-
sue in a lab subject to CLIA using similar methods to 
those previously described.18 After the germline and 
tumor WES reports are generated (turnaround time 
being 3 to 4 months), they are placed into the elec-
tronic health record and disclosed to the parents by the 
patient’s primary oncologist and study genetic coun-
selor. Thus, this study specifically overlaps the clinical 
and research settings, as the clinically validated exome 
results performed through participation in the proto-
col are deposited in the medical record and available 
to the physicians and other medical professionals car-
ing for the patient and the parents. 
Although it was anticipated to be uncommon, if the 
patient died prior to disclosure of the exome results, 
the initial protocol detailed contacting the family 
through the primary oncologist. The disclosure could 
be done in person or by phone in accordance with 
the family’s preferences. Following the disclosure of 
results, the family would be provided with a counsel-
ing letter that would also be placed in the electronic 
health record. In practice, failure to disclose results 
prior to the child’s demise sometimes occurred if the 
family became overwhelmed with their child’s can-
cer care or if the child was enrolled in a cancer treat-
ment protocol at another institution. The cases out-
lined below discuss scenarios in which results were 
returned or attempted to be returned after the death 
of the research participant in this study. 
Case 3: A 5-year-old child was enrolled in the 
BASIC3 study based on the diagnosis of adrenal cor-
tical carcinoma (ACC). This tumor type has a strong 
correlation to a rare cancer susceptibility syndrome, 
Li Fraumeni syndrome, associated with changes in a 
gene called TP53.19 Germline WES identified a novel 
germline TP53 variant which was felt to be the cause 
of the child’s ACC and diagnostic of Li Fraumeni syn-
drome. These results were reported by the laboratory 
one month after the child’s death. Working with the 
primary oncologist, the family returned 5 months 
after the death of the child to an affiliated hospital to 
discuss the results of the genomic testing. The parents, 
the primary oncologist, a study PI (clinical geneticist), 
and a social worker were all present at the disclosure 
visit. Much of the initial discussion surrounded events 
related to the death of the child. Only after those ques-
tions were answered did the parents want to discuss 
the genomic test results. Recommendations were 
made for additional family members to be tested for 
the same TP53 variant found in the proband, and the 
family has followed up with these recommendations.
Case 4: A 3-year-old child was enrolled in the 
BASIC3 study based on the diagnosis of Wilms tumor 
(kidney cancer). The WES results showed no action-
able tumor or germline mutations. The results became 
available 2 months prior to the child’s death, but the 
disclosure visit was unable to be scheduled during this 
time due to the child’s illness. The disclosure visit was 
ultimately scheduled 11 months after the child’s death 
and was held in the oncology clinic. The parents, study 
PI (clinical geneticist), study genetic counselor, and the 
primary oncologist were present. Similar to Case 3, the 
primary focus of the conversation centered on the care 
of the child in the latter portion of illness, followed by 
a relatively short discussion of the genomic test result. 
Case 5: A 3-year-old child was enrolled in the 
BASIC3 study based on the diagnosis of malignant 
melanoma. The tumor report identified a pathogenic 
mutation that had also been identified through other 
test methods and the germline report contained no 
significant findings. The WES results became avail-
able 3 days prior to the child’s death and were pro-
vided to the treating oncologist but were not disclosed 
due to the critical nature of the child’s illness and lack 
of additional findings. The disclosure was scheduled 
with the parents one month following the child’s death 
and was done over the phone by request of the fam-
ily. The father, primary oncologist, study PI (also an 
oncologist), and study genetic counselor were pres-
ent on the call. Upon reaching the father, he felt that 
he was not ready for the conversation. He requested 
that the counseling letter and results simply be sent 
to the family and not discussed further on the phone. 
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The counseling letter provided to each study family 
includes a detailed description of test results written 
in family friendly language and includes contact infor-
mation for study staff. The study protocol does not 
require the family to complete the disclosure process 
to obtain this information; therefore, the counseling 
letter was provided to the father as requested.
Case 6: A 9-year-old child was enrolled on the 
BASIC3 study based on the diagnosis of osteosarcoma. 
The WES results contained no significant findings and 
became available 3 months prior to the death of the 
child. However, by this time the child had transferred 
care from the home institution to another institution 
for enrollment into a clinical trial and thus there were 
no opportunities to disclose the results during medi-
cal visits. After the death of the child, the family was 
reached by the study coordinator and they expressed a 
desire to learn the results. However, several attempts 
have been made to contact and/or meet with the fam-
ily and the family has not returned the calls from the 
study team. 
Modification of protocol based on experience: These 
cases from the BASIC3 clinical sequencing study high-
light several lessons learned in the process of returning 
results to the families of deceased patients. The first 
of these relates to timing: given the family in crisis, 
the results of genomic testing may not be an immedi-
ate priority of the family. In the cases involving return 
of results, even in light of significant findings, obser-
vations showed that families were in greater need of 
discussing the clinical course and loss of their child 
rather than the results of testing. In some cases, fami-
lies expressed interest in the information but were not 
prepared to engage in detailed discussion; some fami-
lies have failed to follow-up altogether despite knowl-
edge of availability of results in the deceased child’s 
medical record.
Based on lessons gleaned from the experiences of 
return of results of deceased patients, the study proto-
col has been adapted to better meet the needs of fami-
lies. The plan for contact of family and return of WES 
results coordinated through the primary oncologist 
(and based on parental preference) remains in place. 
However, adjustments were made to the study proto-
col in the event that the study team is unable to sched-
ule the disclosure. Given that WES results are in the 
electronic medical record, a counseling letter describ-
ing WES results is placed within the medical record 
and the oncologist is notified. A certified letter is then 
sent to the family notifying them that results and a 
counseling letter are available and have been included 
in their child’s medical record. The family is provided 
the option to contact their child’s oncologist or study 
staff at any time to discuss these results or to request 
that we provide this information to another physi-
cian of their choice. Since this protocol modification 
was approved, certified letters are being sent out after 
three unsuccessful attempts to reach the family over 
time. However, choosing a consistent window of time, 
i.e., 6-12 months following the death of the child, dur-
ing which letters will be mailed could be considered.
Elements of the Preventive Ethics Approach
A preventive ethics approach uses the informed con-
sent process to anticipate and seek to minimize ethi-
cal challenges that can be expected to arise in a spe-
cific clinical context. In pediatric genomic research, 
these potential ethical challenges are shaped by the 
timing, nature, and scope of results to be returned. A 
successful preventive ethics approach should there-
fore address the risks of non-disclosure, be sensitive 
to timing, take study design and the types of results 
being disclosed into account, and be responsive to 
ethical concerns. There should also be a well-defined 
and uniformly deployed protocol, beginning with the 
approach of families about potentially entering the 
study which is described here based on ethical princi-
ples and our experience with pediatric cancer human 
subjects research.
A preventive ethics approach uses the informed consent process to anticipate 
and seek to minimize ethical challenges that can be expected to arise in a 
specific clinical context. In pediatric genomic research, these potential ethical 
challenges are shaped by the timing, nature, and scope of results to be returned. 
A successful preventive ethics approach should therefore address the risks of 
non-disclosure, be sensitive to timing, take study design and the types of results 
being disclosed into account, and be responsive to ethical concerns.
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A. Ethical Concerns 
Rights specific to child research participants can be 
interpreted from the 1989 Convention on the Rights 
of the Child, including foremost consideration of 
the best interests of the child, the right to the high-
est attainable standard of health, and the right to 
be heard, which evolves with increased maturity.20 
Required assent, including respect for dissent, based 
on the patient’s age, maturity, and psychological state 
during the informed consent process ensures protec-
tion of these rights. Parental duty within their author-
ity for decision making must be weighed with the 
child’s right to autonomy and an open future, as the 
best interests of the child “is embedded in and depen-
dent on the interests of the family unit.”21 Avard et al. 
stress, “in the context of pediatric research, it is very 
important to be aware of the ‘familial context’ of the 
return of ‘individual’ results.”22 The researcher must 
balance ethical principles while considering both the 
child and the parents as a part of a “tripartite relation-
ship” among the child, parent and researcher.23 This is 
especially applicable in the context of genomic testing 
where results may have direct impact on the parents, 
their other children, and extended family members. 
Additional complexities such as biological relation-
ships, returning results in the context of divorce, as 
well as identifying the appropriate legal guardian for 
return of results must also be considered as a part 
of this relationship. As a part of the BASIC3 proto-
col, one parent is identified as the “primary parent.” 
It is only required that the primary parent be present 
for disclosure of results. However, given that paren-
tal samples are requested for result interpretation, it 
is explained to each parent at the time of enrollment 
that they may receive information regarding their 
own genetic status as part of participation within the 
study. It is also explained that this information may be 
included within the child’s report. Although parental 
samples are encouraged, a parent can decline to pro-
vide a sample and this will not affect the child’s eligi-
bility for the study. The study team encourages both 
parents to be present at the time of disclosure when 
possible and offers the opportunity for any absent par-
ent to discuss research results with a study genetic 
counselor if no legal reason, e.g., custody rulings are in 
place to prevent this. Finally, researchers may have an 
ongoing clinical relationship with the pediatric par-
ticipant and his or her family members, and therefore 
may feel additional responsibility towards the rights of 
the patients and their family members. 
B. Risks of Non-Disclosure 
Given the lack of guidance for return of results after 
the death of a research subject, investigators may 
design and have approved protocols that do not pro-
vide for return of results. However, as described in 
Case 1, there are risks to families of protocols that do 
not allow for return of results. Many years after the 
death of the subject the research results may be of sig-
nificant interest to the family and, given the death of 
the child, there may be no other option to the family 
for obtaining this information other than the return of 
research results. 
Conversely, some parents may refuse the offer 
of return of results. The ethics of informed refusal 
include an obligation to explain to parents the risks 
they are taking, of which they may be unaware. There 
are risks to parents, siblings, and future children of 
non-disclosure when results have clinical significance 
for them or might come to have such significance in 
the future. In addition, there may be the risk of a kind 
of “non-buyers’ remorse” in which not having results 
may be troubling to parents for many years. The pur-
pose of informed refusal is not to pressure parents but 
to support them in reaching an informed and delib-
erative decision not to receive results.
C. Timing
Consistent with other reports, our experience is that 
almost all parents request research results when pro-
vided the opportunity to receive them when their child 
is entering a research protocol. However, parents may 
not want the results in the immediate period, or even 
within a year, of the child’s death. At that time, their 
focus tends to be on the continued coming to terms 
with their profound loss, which could subtly distort 
or even undermine the disclosure process, especially 
helping parents cope with what can often be cogni-
tively demanding information. Some parents may not 
want information until several years later, prompted 
by planning for or the clinical evaluation of a cur-
rent pregnancy. Thus, investigators need to take this 
extended timeframe into account when planning for 
return of results.
D. Importance of Study Design and the Type of 
Results to Be Disclosed
There is much ethical debate about the return of 
genomic research results, both during a participant’s 
life and after death.24 There is also ongoing dialogue 
about the special considerations for returning results 
in the pediatric setting.25 However, not enough atten-
tion has been paid to how study design influences the 
types of results that are generated, which affects deci-
sions about the return of results. For example, results 
from a large-scale GWAS study, which studies the 
association of common variations in the genome with 
disease, may have less immediate clinical relevance to 
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a patient participant’s family than results from a small 
study of a rare disease that has the potential to iden-
tify a mutation associated with a high risk of severe 
disease within a family. Whole exome sequencing 
(WES) and whole genome sequencing (WGS) exam-
ine all coding genes or the entire genome respectively 
for both rare and common genetic variation and 
therefore opens the doors to the possibility of inci-
dental findings unrelated to the original indication 
for testing.26 As research moves into the genomic era 
and clinical tests are being used in research settings, 
the potential for identification of incidental findings 
increases and the boundary between research and 
clinical care will become more difficult to define as 
will the scope of return of results.27 When planning 
for the disclosure of research results, it is impor-
tant to distinguish the types of results that will be 
returned and whether they will include only those 
related to the indication for research participation 
or also include incidental findings.28 A lack of clarity 
as to what will be disclosed, whether it be findings 
of unclear significance, incidental findings unrelated 
to the child’s illness or an absence of clinically sig-
nificant findings can complicate the disclosure to a 
family who has recently lost a child, particularly as 
parents may be trying to seek answers as to the cause 
of their child’s illness or address concerns for siblings 
or future pregnancies. 
E. Importance of a Protocol to Improve Quality 
A simple approach to the improvement of quality is to 
“do it the same way every time.” A more sophisticated 
approach is to “do it the right way every time.” The lat-
ter increases the likelihood of professionally respon-
sible minimization of variation, as variation in process 
may result in variation in quality of disclosure. A pro-
tocol to guide the preventive ethics approach should 
be understood in the context of improving the quality 
of return of results in pediatric genomic research. It 
is therefore essential to anticipate possible research 
results and have a clear protocol for return of results 
after the death of pediatric research participants. 
When appropriate, this should be specified during 
informed consent and patient participant and family 
preferences should be considered. The informed con-
sent process and procedures for returning genomic 
research results to pediatric patients and their fami-
lies must be a particularly flexible process, involving 
the parents and adjusting to the increasing capacity of 
the patient’s ability to assent, and eventually consent 
upon the age of majority. 
A particularly significant issue in return of results 
after death in the pediatric setting is the balance 
between the priorities of a grieving parent and the 
need for flexibility on the setting, method, and timing 
of disclosure. As described in our case studies, even 
in the setting of having medically significant genomic 
results to return, parents often wanted to spend more 
time discussing the clinical care and treatment of 
their child, and particularly events around the time 
of death, with caregivers (who may also be involved 
in the research study). Some families either actively 
or passively declined the discussion of genomic test 
results in this scenario. Over time, this information 
may grow in importance to families, particularly 
when planning future pregnancies or care for sib-
lings of the deceased proband. For this reason, it will 
become increasingly critical to build a mechanism 
into return of results protocols that makes participat-
ing families aware that research results are available 
to them and that these results can be disclosed at the 
time most appropriate to the circumstances of the 
family even if the initial research goals of the study 
have been completed. 
Conclusion
The return of research results after death specific to 
the pediatric cancer genetic setting has unique com-
plexities. Within any pediatric setting, researchers 
are working with a family unit that extends beyond 
the proband. Genomic research results may affect not 
only the child but parents, siblings, and future repro-
ductive decision making. For many families, the pos-
sibility of return of results is promising in their search 
for answers. However, in the context of the loss of a 
child, a family may have more immediate needs, such 
as having questions answered about the end-of-life 
care for their child and coping through the grieving 
process itself. For this reason, it is important to create 
a preventive ethics approach to the return of results 
after death that make results available to families in 
a protocol that supports flexibility for this to be done 
based on the family’s needs and preferences when pos-
sible. The experiences of BCM researchers highlighted 
here demonstrate that this may need to be a fluid pro-
cess, but overall, the ability to provide families with 
the option for return of results is welcomed by the 
majority of families. Including a well outlined proto-
col for return of results after death into IRB protocols 
will become even more important given the increasing 
development of genomic studies that balance the fine 
line between research and clinical care. 
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